ReviewNaunyn-Schmiedeberg's archives of pharmacology2006
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 58 citations in OpenAlex.
- Pharmacokinetic Drug-Drug Interactions of DA-8010 with Clarithromycin or Rifampicin: Influence of CYP2D6 Phenotype on the Extent of These Interactions.Drug design, development and therapy · 2026Trial
- Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.European journal of clinical pharmacology · 2008Trial
- An Updated Structure of Oxybutynin Hydrochloride.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- An Updated Structure of Oxybutynin Hydrochloride.bioRxiv : the preprint server for biology · 2024Article
- Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.Drugs & aging · 2012Review
- Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine.Naunyn-Schmiedeberg's archives of pharmacology · 2010Article
- Role of fesoterodine in the treatment of overactive bladder.Open access journal of urology · 2009Review
- Urothelial effects of oral agents for overactive bladder.Current urology reports · 2008Review
- Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity.International urogynecology journal and pelvic floor dysfunction · 2008Article
- In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.Naunyn-Schmiedeberg's archives of pharmacology · 2008Article
- Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors.Naunyn-Schmiedeberg's archives of pharmacology · 2008Review
- Electrophysiological profile of propiverine--relationship to cardiac risk.Naunyn-Schmiedeberg's archives of pharmacology · 2008Article
- Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes.The Journal of pharmacology and experimental therapeutics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antagonists of muscarinic acetylcholine receptors, such as darifenacin, oxybutynin, propiverine, solifenacin, tolterodine, and trospium, are the mainstay of the treatment of the overactive bladder syndrome. Fesoterodine is a newer drug awaiting regulatory approval. We briefly review the pharmacological activity of their metabolites and discuss how active metabolites may contribute to their efficacy and tolerability in vivo. Except for trospium, and perhaps solifenacin, all of the above drugs form active metabolites, and their presence and activity need to be taken into consideration when elucidating relationships between pharmacokinetics and pharmacodynamics of these drugs. Moreover, the ratios between parent compounds and metabolites may differ depending on genotype of the metabolizing enzymes, concomitant medication, and/or drug formulation. Differential generation of active metabolites of darifenacin or tolterodine are unlikely to influence the overall clinical profile of these drugs in a major way because the active metabolites exhibit a similar pharmacological profile as the parent compound. In contrast, metabolites of oxybutynin and propiverine may behave quantitatively or even qualitatively differently from their parent compounds and this may have an impact on the overall clinical profile of these drugs. We conclude that more comprehensive studies of drug metabolites are required for an improved understanding of their clinical effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.